Plain-English translation of NCT06749899 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new immunotherapy medication, combined with chemotherapy and radiation therapy for people with advanced nasopharyngeal cancer (a type of throat cancer). About half of participants will receive the standard treatment of chemotherapy and radiation alone, while the other half will receive the same treatment plus the medication. Researchers want to see whether adding this medication helps fight the cancer more effectively.
Current treatments for advanced nasopharyngeal cancer work well for some patients, but many still experience cancer recurrence. This medication is designed to strengthen your body's natural immune system to better recognize and destroy cancer cells, which may improve survival rates.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive three cycles of chemotherapy over about 9 weeks, followed by radiation therapy given over about 6-7 weeks with concurrent chemotherapy. If assigned to the medication group, you will also receive injections of every three weeks starting with your first chemotherapy dose and continuing for up to 12 total doses (during and after your main treatment). The entire treatment course will take several months, with regular blood tests and imaging scans to monitor your progress and side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China